Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369530 | PMC |
| http://dx.doi.org/10.1016/j.opresp.2020.100080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Asymptomatic thrombocytopenia after nintedanib initiation in a patient with progressive pulmonary fibrosis: a case report and review of literature.
J Med Case Rep
September 2024
College of Pulmonary and Critical Care Medicine, the 8th Medical Center of Chinese PLA General Hospital, Beijing, China.
Article Synopsis
- Nintedanib is a medicine used to treat certain lung diseases, but it can sometimes cause low platelet counts (thrombocytopenia).
- A 60-year-old man started taking nintedanib for his lung disease, and his platelet count dropped quickly but improved after stopping the medicine.
- Doctors believe that the low platelet levels caused by nintedanib can usually be fixed and that patients should be closely watched while on this medication.
Antifibrotics in the Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Prospective Real-World Experience From an Interstitial Lung Disease Clinic in India.
Cureus
June 2024
Pulmonary Medicine, All India Institute of Medical Sciences, Raipur, Raipur, IND.
Background & Objectives: Interstitial lung disease (ILD) in rheumatoid arthritis (RA) is a serious complication with varied prevalence ranging from 4% to as high as 68%, with varied presentation. Immunosuppressants and antifibrotics are used in the management of RA ILD. The clinicodemographic profile and presentation in our country need to be further explored.
View Article and Find Full Text PDFAssociation between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients.
BMC Pulm Med
March 2024
Mayo Clinic, Rochester, MN, USA.
Background: Although inverse associations have been found between medication adherence and healthcare use and spending outcomes in many clinical settings, no studies to date have examined these relationships for patients with idiopathic pulmonary fibrosis (IPF) initiating nintedanib. We build on our prior study that used group-based trajectory modeling (GBTM) to compare inpatient hospitalization and medical care spending outcomes between groups of patients with different nintedanib adherence trajectories.
Methods: This analysis used 100% Medicare data and included beneficiaries with IPF who initiated nintedanib during 10/01/2014-12/31/2018.
Comparison of nintedanib-induced gastrointestinal adverse events between patients with systemic sclerosis-associated interstitial lung disease and idiopathic interstitial pneumonias.
Respir Investig
May 2024
Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Article Synopsis
- Gastrointestinal symptoms, specifically diarrhea and nausea, are common with nintedanib treatment, especially in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
- A study compared adverse gastrointestinal events between SSc-ILD and idiopathic interstitial pneumonias (IIPs) patients who were treated with nintedanib, finding no significant difference in treatment duration.
- Results showed that SSc-ILD patients experienced more nausea and similar rates of diarrhea compared to those with IIPs, suggesting a need for improved management of these adverse effects in SSc-ILD patients.
Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study.
Pharmaceuticals (Basel)
January 2024
Department of Pulmonology, University Hospital of Cattinara, 34149 Trieste, Italy.
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with rapidly progressive evolution and an unfavorable outcome. Nintedanib (NTD) is an antifibrotic drug that has been shown to be effective in slowing down the progression of the disease. The aim of our study was to examine the efficacy, especially in terms of the functional decline, and the safety profile of NTD in patients treated with the recommended dose and subjects who reduced or suspended the therapy due to the occurrence of adverse reactions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!